Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus FLONASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus FLONASE.
CORTIFOAM vs FLONASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as cytokines, leukotrienes, and prostaglandins, thereby reducing nasal inflammation.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
2 sprays (50 mcg/spray) per nostril once daily; may increase to 2 sprays per nostril twice daily if needed. Intranasal route.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life is approximately 3 hours (range 2-4 hours). This short half-life supports twice-daily dosing for systemic effects; however, intranasal administration achieves local therapeutic concentrations with minimal systemic exposure.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily hepatic metabolism (CYP3A4), with metabolites excreted in feces (approximately 87-90%) and urine (<5% unchanged). Less than 5% of a dose is excreted renally as unchanged drug.
Category C
Category C
Corticosteroid
Corticosteroid